Eiger BioPharmaceuticals, Inc. (EIGR) Can’t Be More Risky. The Stock Formed a Bearish Multiple Bottom Chart Pattern

June 12, 2018 - By Rene Maslow

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

The stock of Eiger BioPharmaceuticals, Inc. (EIGR) shows a multiple bottoms pattern with $13.97 target or 5.00 % below today’s $14.70 share price. The 6 months chart pattern indicates high risk for the $201.92 million company. It was reported on Jun, 12 by Finviz.com. If the $13.97 price target is reached, the company will be worth $10.10 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 0.68% or $0.1 during the last trading session, reaching $14.7. About 144,901 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has risen 88.41% since June 12, 2017 and is uptrending. It has outperformed by 75.84% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.82 earnings per share, up 38.35 % or $0.51 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -2.38 % EPS growth.

More recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Seekingalpha.com which released: “Eiger Bio -5% with $40M offering said to come at $12.50/share” on May 23, 2018. Also Streetinsider.com published the news titled: “Eiger BioPharmaceuticals (EIGR) Prices 3.2M Common Stock Offering at $12.50/Share” on May 24, 2018. Streetinsider.com‘s news article titled: “After-Hours Stock Movers 05/23: (BW) (WSM) (SMRT) Higher; (LB) (NTAP) (EIGR) Lower (more…)” with publication date: May 23, 2018 was also an interesting one.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $201.92 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.